Tag Archives: health care industry

Spinal implant allows Parkinson’s patient to walk for miles

Posted on by

A Parkinson’s patient can now walk 6km (3.7 miles) thanks to an implant targeting the spinal cord. The Guardian reports that the man — 62-year-old “Marc” from Bordeaux, France — developed severe mobility impairments from the degenerative disease. “I practically could not walk anymore without falling frequently, several times a day,” he said in a press release announcing the breakthrough. “In some situations, such as entering a lift, I’d trample on the spot, as though I was frozen there, you might say.” Wearing the spinal implant allows him to walk “almost normally” as the research team eyes a full clinical trial.

Marc underwent a “precision neurosurgical procedure” two years ago at Lausanne University Hospital (CHUV), which helped facilitate the research. The surgery fitted him with an electrode field placed against his spinal cord and an electrical impulse generator under the skin of his abdomen. Although conventional Parkinson’s treatments often target brain regions affected by the loss of dopamine-producing neurons, this approach instead focuses on the spinal area associated with activating leg muscles for walking.

The procedure used a personalized map of Marc’s spinal cord, identifying the specific locations signaling leg movements. He wears a movement sensor on each leg that tells the implant he’s trying to walk; it then switches on and sends electrical impulses to the targeted spinal neurons, adapting to his movement in real-time.

Swiss neurosurgeon, professor and co-director of NeuroRestore Jocelyne Bloch (L) and Swiss professor of neuroscience at the Swiss Federal Institute of Technology in Lausanne (EPFL) Lausanne University Hospital (CHUV) and Lausanne University (UNIL) and co-director of NeuroRestore, Gregoire Courtine (R), walk with Marc (C) a French patient suffering from Parkinson's disease fitted with a new neuroprosthesis during the presentation of a new neuroprosthesis that restores fluid walking in Lausanne, on November 3, 2023. Neuroscientists from Inserm, CNRS and the University of Bordeaux in France, together with Swiss researchers and neurosurgeons (EPFL/CHUV/UNIL), have designed and tested a 'neuroprosthesis' designed to correct the walking problems associated with Parkinson's disease. (Photo by GABRIEL MONNET / AFP) /
GABRIEL MONNET via Getty Images

“In response to precise stimulation of the lumbar spinal cord, I’ve observed for the first time remarkable improvements of gait deficits due to Parkinson’s disease,” project supervisor Jocelyne Bloch, professor and neurosurgeon at CHUV Lausanne University hospital, said in a webinar discussing the patient’s success. “I really believe that these results open realistic perspectives to develop a treatment.”

The patient says he could walk practically normally with the stimulation after several weeks of rehab. He now wears it for around eight hours daily, only turning it off when sleeping or lying down for a while. “I turn on the stimulation in the morning and I turn off in the evening,” he said. “This allows me to walk better and to stabilise. Right now, I’m not even afraid of the stairs anymore. Every Sunday I go to the lake, and I walk around 6 kilometres. It’s incredible.”

The researchers caution that there’s still a vast chasm between tailoring the approach to one person vs. optimizing it for wide-scale use. Co-leads Grégoire Courtine and Bloch are working on a commercial version of the neuroprosthetic in conjunction with Onward Medical. “Our ambition is to provide general access to this innovative technology to improve the quality of life of Parkinson’s patients significantly, all over the world,” they said.

Sting (left) and Michael J. Fox jam on guitars onstage at a 2021 benefit.
Michael J. Fox (right) with Sting.
Michael J. Fox Foundation

In the meantime, research on six new patients will continue in 2024. The team says a “generous donation” of $1 million from the Michael J. Fox Foundation for Parkinson’s Research is funding the upcoming work. In 2021, the actor’s organization announced it had contributed over $1.5 billion to Parkinson’s research.

This article originally appeared on Engadget at https://www.engadget.com/spinal-implant-allows-parkinsons-patient-to-walk-for-miles-193637427.html?src=rss

The ARC nerve-stimulation system could help quadriplegic patients move their arms again

Posted on by

The ARC nerve stimulation therapy system from startup Onward Medical passed another developmental milestone on Wednesday, as the company announced the first successful installation of its brainwave-driven implantable electrode array to restore function and feeling to a patient’s hands and arms. The news comes just five months after the researchers implanted a similar system in a different patient to help them regain a more natural walking gait.

The ARC system used differs depending on how what issue it's being applied to. The ARC-EX is an external, non-invasive stimulator array that sits on the patient’s lower back and helps regulate their bladder control and blood pressure, as well as improving limb function and control. Onward’s lower limb study from May employed the EX along with a BCI controller from CEA-Clinatec to create a “digital bridge” spanning the gap in the patient’s spinal column.

The study published Wednesday instead utilized the ARC-IM, an implantable version of the company’s stimulator array which is installed near the spinal cord and is controlled through wearable components and a smartwatch. Onward had previously used the IM system to enable paralyzed patients to stand and walk short distances without assistance, for which it was awarded an FDA Breakthrough Device Designation in 2020.

Medical professionals led by by neurosurgeon Dr. Jocelyne Bloch, implanted the ARC-IM and the Clinatec BCI into a 46-year-old patient suffering from a C4 spinal injury, in mid-August. The BCI’s hair-thin leads pick up electrical signals in the patient’s brain, convert those analog signals into digital ones that machines can understand, and then transmits them to a nearby computing device where a machine learning AI interprets the patient’s electrical signals and issues commands to the implanted stimulator array. The patient thinks about what they want to do and these two devices work to translate that intent into computer-controlled movement.

How well that translation occurs remains to be seen while the patient learns and adapts to the new system. “The implant procedures involving the Onward ARC-IM and Clinatec BCI went smoothly,” Dr. Bloch said in an press release. “We are now working with the patient to use this cutting-edge innovation to recover movement of his arms, hands, and fingers. We look forward to sharing more information in due course.”

“If the therapy continues to show promise, it is possible it could reach patients by the end of the decade,” Onward CEO Dave Marver said in a statement to Engadget. “It is important to note that we do not expect people with spinal cord injury to wait that long for Onward to commercialize an impactful therapy - we hope to commercialize our external spinal cord stimulation solution, ARC-EX Therapy, to restore hand and arm function in the second half of 2024.”

Onward Medical among a quickly expanding field of BCI-based startups working to apply the fledgling technology to a variety of medical maladies. Those applications include loss of limb and self-regulatory function due to stroke, traumatic brain or spinal cord injury, physical rehabilitation from those same injuries, as well as a critical means of communication for people living with Locked-In Syndrome.

This article originally appeared on Engadget at https://www.engadget.com/the-arc-nerve-stimulation-system-could-help-quadriplegic-patients-move-their-arms-again-053027395.html?src=rss

Google is developing an AI-powered microscope to help doctors spot cancer

Posted on by

Google has prototyped an “Augmented Reality Microscope,” (ARM) in conjunction with the Department of Defense, which incorporates artificial intelligence enhancements to overlay visual indicators, like heatmaps or object boundaries, in real-time. The AI additions allegedly make it easier to classify samples and identify the presence of cancer cells or pathogens.

The ARM was first teased publicly in 2018 and has not been used to diagnose patients yet. Currently, 13 prototypes of the ARM exist, with significant testing still needed before it can assist everyday clinicians. However, the intention is to create a system that can be "retrofitted into existing light microscopes found in hospitals and clinics," according to Google. ARM-equipped microscopes can then provide a variety of visual feedback, including text, arrows, contours, heat maps, or animations, each tailored to unique assessment goals.

The Department of Defense's Defense Innovation Unit has reportedly negotiated agreements with Google that will enable ARM distribution through the military, according to CNBC, with the hope that it could be available to some government users sometime this fall. ARM is expected to cost between $90,000 and $100,000 — likely well beyond the means of local health providers. We've asked Google for more information on the progress of the program and potential timeline of availability and will update if we hear back.

This is not the first time Google Health has dipped its toes in investing in AI-powered tools that not only improve the accuracy of diagnostics but also help fill gaps in medicine where there is limited availability of healthcare personnel. The tech giant has made it a point to partner with startups that invest in AI to “improve healthcare” and is projected to have invested upwards of $200 billion on AI investments in the past decade, according to Reuters. This is especially noteworthy considering the World Health Organization predicts a shortfall of 15 million health care workers worldwide by 2030.

This article originally appeared on Engadget at https://www.engadget.com/google-is-developing-an-ai-powered-microscope-to-help-doctors-spot-cancer-181507943.html?src=rss

GE Health is working on AI-powered ultrasounds to combat pediatric and maternal mortality rates

Posted on by

GE Health says it plans to develop an AI-assisted ultrasound imaging tool that is so simple, that even healthcare providers without specialized training will be able to use it. The research and development will be funded by a $44 million grant from the Bill & Melinda Gates Foundation, which has historically invested in the roll-out of new technologies in resource-poor settings to address gaps in healthcare access.

GE Health says the AI-powered imaging technology has been designed to be dispersed to low-and-middle income countries where the services of healthcare providers may be stretched thin. The assessment tools will be more effective at providing clear readings of lung and ultrasound scans across maternal and fetal care as well as pediatric lung health — and will be compatible with a number of inexpensive ultrasound devices. These areas of medicine are particularly notable because maternal and child mortality is mostly preventable if medical intervention occurs early. Proper medical imaging is key to achieving timely diagnosis, guides treatment decisions and can improve treatment outcomes.

GE Health’s $3 billion ultrasound business, has recently focused on the development pipeline of AI software with the acquisition of med tech companies like Caption Health, which will help design this particular tool. The company appears committed to a strategy of increasing spending on AI-related projects both now and in the near future.

Correction, Sept. 19th, 2023, 9:24AM ET: A prior version of this story conflated the intended goal (AI-assisted imaging tools) with its application (ultrasound devices themselves), and referred to the independent GE Health unit as simply GE. 

This article originally appeared on Engadget at https://www.engadget.com/ge-is-working-on-ai-powered-ultrasounds-to-combat-pediatric-and-maternal-mortality-rates-034020572.html?src=rss

An experimental rice-sized implant monitors how drugs affect tumors

Posted on by

Researchers at Brigham and Women’s Hospital in Boston have developed an implant, notably as small as a grain of rice, that can test the effects of drugs on a patient’s brain tumor in real-time during surgery. Currently, monitoring the effects of drugs on a brain cancer patient during surgery is limited to intraoperative brain imaging and tissue sampling after a drug has been administered. The technique known as microdialysis currently stands as one of the more minimally invasive sampling options for testing the impact of drugs on brain tumors, but even that requires an entire catheter to be inserted into the patient’s skull cavity.

During development, researchers from Brigham and Women’s Hospital designed the device specifically to help test treatments in patients with brain cancers or gliomas, a type of tumor that originates in the brain or spinal cord. The device is designed to only remain implanted in a patient for about two to three hours while it delivers microdoses of the respective drug that is under observation. It can observe the impact of up to 20 drugs on the market for cancerous tumors, according to the researchers. Once the device is removed (sometime before the surgery ends), the surrounding tissue is returned to the lab for analysis.

In a statement published Wednesday, Pierpaolo Peruzzi, co-principal investigator and assistant professor in the Department of Neurosurgery at Brigham and Women’s Hospital said that knowing the impact of cancer drugs on these tumors is critical. “We need to be able to understand, early on, which drug works best for any given patient,” he said.

Brigham and Women’s Hospital building pictured
Brigham and Women’s Hospital

During the development process, researchers at the Brigham and Women’s Hospital ran a clinical trial to observe the actual impact of the implant on real patients. The study found that none of the patients in the trial experienced any adverse effects. The researchers were able to collect biological data from the devices, such as what molecular changes happened when each drug was administered. While the study demonstrated that the implant could be easily incorporated into surgical practice, the researchers are still determining how the data it can gather should be used to optimize tumor therapy.

The researchers are now conducting another study that focuses on implanting the device through a minimally invasive procedure 72 hours before their main surgery. Advancements in the cancer treatment space continue to expand, with new iterations of drug cocktails and viruses that can fight cancer cells emerging in the biotech space. Implants like the one developed by the Brigham and Women’s Hospital bring scientists one step closer to better being able to use tools and data to provide more personalized care treatment plans for cancer patients.

This article originally appeared on Engadget at https://www.engadget.com/an-experimental-rice-sized-implant-monitors-how-drugs-affect-tumors-210038580.html?src=rss

An experimental rice-sized implant monitors how drugs affect tumors

Posted on by

Researchers at Brigham and Women’s Hospital in Boston have developed an implant, notably as small as a grain of rice, that can test the effects of drugs on a patient’s brain tumor in real-time during surgery. Currently, monitoring the effects of drugs on a brain cancer patient during surgery is limited to intraoperative brain imaging and tissue sampling after a drug has been administered. The technique known as microdialysis currently stands as one of the more minimally invasive sampling options for testing the impact of drugs on brain tumors, but even that requires an entire catheter to be inserted into the patient’s skull cavity.

During development, researchers from Brigham and Women’s Hospital designed the device specifically to help test treatments in patients with brain cancers or gliomas, a type of tumor that originates in the brain or spinal cord. The device is designed to only remain implanted in a patient for about two to three hours while it delivers microdoses of the respective drug that is under observation. It can observe the impact of up to 20 drugs on the market for cancerous tumors, according to the researchers. Once the device is removed (sometime before the surgery ends), the surrounding tissue is returned to the lab for analysis.

In a statement published Wednesday, Pierpaolo Peruzzi, co-principal investigator and assistant professor in the Department of Neurosurgery at Brigham and Women’s Hospital said that knowing the impact of cancer drugs on these tumors is critical. “We need to be able to understand, early on, which drug works best for any given patient,” he said.

Brigham and Women’s Hospital building pictured
Brigham and Women’s Hospital

During the development process, researchers at the Brigham and Women’s Hospital ran a clinical trial to observe the actual impact of the implant on real patients. The study found that none of the patients in the trial experienced any adverse effects. The researchers were able to collect biological data from the devices, such as what molecular changes happened when each drug was administered. While the study demonstrated that the implant could be easily incorporated into surgical practice, the researchers are still determining how the data it can gather should be used to optimize tumor therapy.

The researchers are now conducting another study that focuses on implanting the device through a minimally invasive procedure 72 hours before their main surgery. Advancements in the cancer treatment space continue to expand, with new iterations of drug cocktails and viruses that can fight cancer cells emerging in the biotech space. Implants like the one developed by the Brigham and Women’s Hospital bring scientists one step closer to better being able to use tools and data to provide more personalized care treatment plans for cancer patients.

This article originally appeared on Engadget at https://www.engadget.com/an-experimental-rice-sized-implant-monitors-how-drugs-affect-tumors-210038580.html?src=rss

Biometric implant monitors transplant patients for organ rejection

Posted on by

Researchers at Northwestern University developed a bioelectric implant that can detect temperature fluctuations that typically happen right before a body rejects an organ transplant. The sensor is smaller than a fingernail, and a mere 220 micrometers thick.

This new sensor technology is thin enough to sit directly on a kidney's fibrous layer — called the renal capsule — which surrounds and protects the organ. The device works by continuously monitoring changes to blood flow and temperature. The built-in thermometer can sense increases as minuscule as 0.004 degrees Celsius. Once an irregularity is detected, the sensor, which contains a micro coin cell battery for power, uses Bluetooth to alert a patient or physician via a smartphone or tablet. Any increase typically signals inflammation which is a potential sign of transplant rejection.

After any surgery that involves an organ transplant, the risk of rejection is high. The sensor was developed specifically for kidney transplants but it could also work for other organs, including the liver and lungs. Kidney transplants in the US are on the rise and are usually recommended for people who will not be able to live without dialysis. The American Kidney Fund cites that an acute rejection of a kidney transplant one month after surgery happens in about five to twenty percent of patients that go under.

That’s why it is critical to detect transplant rejection, which occurs when your body's immune system treats the new organ like a foreign object and attacks it. If a healthcare provider detects signs of rejection early enough, medical intervention can preserve the new organ in the new host. Northwestern researchers said that the device detected warning signs of organ rejection three weeks earlier than current monitoring methods. The current “gold standard” for detecting rejection is a biopsy, where a tissue sample is extracted from the transplanted organ and then analyzed in a lab. However, biopsies are invasive and can cause bleeding and increase the risk for infection.

An infrared camera glows red where the thermometer detects a subtle source of heat.
Northwestern University

Despite developing an innovative first-of-its-kind product, researchers at Northwestern University still have a long way to go. It still needs to be tested on humans in a clinical setting before it can make any impact in the surgical market. Northwestern’s John A. Rogers, a bioelectronics expert who led the device development, said in a statement that his team is now evaluating ways to recharge the coin cell battery so that it can last a lifetime.

This article originally appeared on Engadget at https://www.engadget.com/biometric-implant-monitors-transplant-patients-for-organ-rejection-180045215.html?src=rss

Biometric implant monitors transplant patients for organ rejection

Posted on by

Researchers at Northwestern University developed a bioelectric implant that can detect temperature fluctuations that typically happen right before a body rejects an organ transplant. The sensor is smaller than a fingernail, and a mere 220 micrometers thick.

This new sensor technology is thin enough to sit directly on a kidney's fibrous layer — called the renal capsule — which surrounds and protects the organ. The device works by continuously monitoring changes to blood flow and temperature. The built-in thermometer can sense increases as minuscule as 0.004 degrees Celsius. Once an irregularity is detected, the sensor, which contains a micro coin cell battery for power, uses Bluetooth to alert a patient or physician via a smartphone or tablet. Any increase typically signals inflammation which is a potential sign of transplant rejection.

After any surgery that involves an organ transplant, the risk of rejection is high. The sensor was developed specifically for kidney transplants but it could also work for other organs, including the liver and lungs. Kidney transplants in the US are on the rise and are usually recommended for people who will not be able to live without dialysis. The American Kidney Fund cites that an acute rejection of a kidney transplant one month after surgery happens in about five to twenty percent of patients that go under.

That’s why it is critical to detect transplant rejection, which occurs when your body's immune system treats the new organ like a foreign object and attacks it. If a healthcare provider detects signs of rejection early enough, medical intervention can preserve the new organ in the new host. Northwestern researchers said that the device detected warning signs of organ rejection three weeks earlier than current monitoring methods. The current “gold standard” for detecting rejection is a biopsy, where a tissue sample is extracted from the transplanted organ and then analyzed in a lab. However, biopsies are invasive and can cause bleeding and increase the risk for infection.

An infrared camera glows red where the thermometer detects a subtle source of heat.
Northwestern University

Despite developing an innovative first-of-its-kind product, researchers at Northwestern University still have a long way to go. It still needs to be tested on humans in a clinical setting before it can make any impact in the surgical market. Northwestern’s John A. Rogers, a bioelectronics expert who led the device development, said in a statement that his team is now evaluating ways to recharge the coin cell battery so that it can last a lifetime.

This article originally appeared on Engadget at https://www.engadget.com/biometric-implant-monitors-transplant-patients-for-organ-rejection-180045215.html?src=rss

Clearblue’s cheap menopause test fills a hole in the at-home health market

Posted on by

Clearblue has launched a new product that can determine what stage of menopause a person is in. The "Menopause Stage Indicator" is a urine testing device and it's the company's first for this underserved market in women's health.

The Menopause Stage Indicator looks like a standard pregnancy test stick but instead of measuring urine for pregnancy hormones, it will look for follicle-stimulating hormone (FSH) levels, which are measured to confirm menopause. To get accurate test results, you’ll have to conduct five urine tests over ten days, and Clearblue recommends they be taken every other day. Using FSH levels, menstrual cycle history, and a person’s age, the company will be able to determine and confirm the menopause stage. The app will calculate if a person is in premenopause, early perimenopause, late perimenopause, or postmenopause.

In its press release, Clearblue acknowledges that only a healthcare professional can confirm someone’s menopause stage. However, through the app, you can generate a personalized report and share it with your healthcare provider to confirm test results and discuss potential treatment options. The Menopause Stage Indicator will be available on Amazon for a starting price of $20.

Women’s health has long been cast aside as a mere subset of healthcare. And it’s even worse for aging people entering menopause. The market for a menopause testing device by Clearblue, a brand most famous for its pregnancy tests, is prime for the taking. Studies show that 73 percent of women experience menopause but do not seek treatment for their symptoms and the global menopause market size is projected to grow to $21.6 billion by 2026.

This article originally appeared on Engadget at https://www.engadget.com/clearblues-cheap-menopause-test-fills-a-hole-in-the-at-home-health-market-230039337.html?src=rss

German Bionic’s latest exoskeleton helps healthcare workers lift elderly patients

Posted on by

German Bionic, the robot exoskeleton startup behind the lightweight Apogee exosuit, just revealed the Apogee+, a hardware refresh intended to service health care workers. The powered exoskeleton allows nurses and other health care professionals to have greater access to patients, particularly the elderly and the infirm. The company hopes to decrease the “immense levels of stress endured” by these medical professionals.

To that end, the Apogee+ is designed as a “personal lift assistant,” providing active assistance while walking, lifting and arranging patients for treatments and sanitary procedures like showers. The robo-suit offers nearly 70 pounds of back relief per lift and includes integrated grips for getting a stable hold on things and for repositioning patients.

Just like its sibling exoskeleton, the Apogee+ is small and lightweight, so it can be worn by a variety of people in a diverse array of environments. It’s also waterproof, which should help when bathing patients, and dust-proof, which should help when, uh, working in rundown medical facilities straight out of a Stephen King novel.

Most German Bionic products, like the powerful Cray X, are designed for industrial settings, but the Apogee+ is made for health clinics, so it features a softer form factor with light “patient-friendly” colors. The suit’s unibody exterior is designed for an easy disinfection process, so germs and bacteria won’t accumulate. This is obviously quite essential in healthcare environments.

German Bionic touts recent data celebrating the efficacy of exoskeleton wearable products in the healthcare space, saying that it “offers flexible and reliable support to nursing staff.” The Apogee+ is rolling out across North America now, so it’s already available for purchase by health care entities. If you want to try it for yourself, book a passage to Germany in November. The company’s offering in-person demos at global medical trade show Medica on November 13. These exoskeletons cost $9,900 or $299 per month forr bulk purchasers. 

This article originally appeared on Engadget at https://www.engadget.com/german-bionics-latest-exoskeleton-helps-healthcare-workers-lift-elderly-patients-130046538.html?src=rss